Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Income: 2015-2025

Historic Non Operating Income for Cartesian Therapeutics (RNAC) over the last 7 years, with Jun 2025 value amounting to -$5,000.

  • Cartesian Therapeutics' Non Operating Income fell 101.71% to -$5,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $93,000, marking a year-over-year decrease of 90.62%. This contributed to the annual value of $606,000 for FY2024, which is 12.30% down from last year.
  • As of Q2 2025, Cartesian Therapeutics' Non Operating Income stood at -$5,000, which was up 98.87% from -$444,000 recorded in Q4 2024.
  • Cartesian Therapeutics' Non Operating Income's 5-year high stood at $508,000 during Q1 2024, with a 5-year trough of -$444,000 in Q4 2024.
  • In the last 3 years, Cartesian Therapeutics' Non Operating Income had a median value of $250,000 in 2024 and averaged $143,556.
  • Its Non Operating Income has fluctuated over the past 5 years, first spiked by 25,200.00% in 2023, then slumped by 616.13% in 2024.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Non Operating Income stood at $9,000 in 2021, then slumped by 88.89% to $175,000 in 2022, then slumped by 135.43% to -$62,000 in 2023, then crashed by 616.13% to -$444,000 in 2024, then plummeted by 101.71% to -$5,000 in 2025.
  • Its last three reported values are -$5,000 in Q2 2025, -$444,000 for Q4 2024, and $250,000 during Q3 2024.